Elicio Therapeutics, Inc. announced on September 17, 2025, immunogenicity testing data from its ongoing Phase 2 AMPLIFY-7P trial. The data showed that approximately 99% of evaluable patients, specifically 89 of 90, who received ELI-002 7P generated strong mKRAS-specific T cell responses.
These robust T cell responses demonstrated an average increase of 145.3x over baseline responses, consistent with observations from prior Phase 1 trials of ELI-002. In earlier Phase 1 studies, T cell immune responses were significantly correlated with clinical activity in minimal residual disease positive (MRD+) patients.
These important immunogenicity data set the stage for the final disease-free survival analysis in the AMPLIFY-7P trial, which is anticipated to occur in the fourth quarter of 2025. The Phase 2 trial's inclusion of MRD-negative patients could also expand the potential commercial opportunity for Elicio if results are supportive.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.